Acquisition - March 6, 2014
Bayer completes voluntary takeover offer for Algeta
The Bayer Group has completed the voluntary takeover offer for Norwegian pharmaceutical company Algeta. According to a statement from Bayer, the payment of the offer price has been made to Algeta’s shareholders who accepted the takeover offer and, at the same time, the 43,131,641 tendered shares have been transferred to Bayer. As a result, Bayer […]
Acquisition - December 20, 2013
Bayer buys Algeta
Bayer plans to acquire Norwegian pharmaceutical company Algeta. The Bayer Group plans to further strengthen its oncology portfolio with the acquisition of Norwegian pharmaceutical company Algeta ASA, Oslo, according to a press release. Bayer has already collaborated with Algeta to develop and commercialize the cancer drug Xofigo. The planned acquisition would give Bayer full control […]
Drug Development Pharma - December 13, 2013
Bayer granted marketing authorization in Norway for prostate cancer treatment
Bayer HealthCare announced recently that the company has received the marketing approval for Xofigo by the Norwegian Medicines Agency. Xofigo (radium Ra 223 dichloride) has been developed by Algeta. In September 2009, the two companies signed an agreement for the further development and commercialization of radium-223. Xofigo is produced in Norway at the Institute for Energy Technology (IFE) at […]
Drug Development Pharma - November 18, 2013
Algeta & Bayer granted EU marketing authorization
Algeta and Bayer have received marketing authorisation from the European Commission for Xofigo for the treatment of prostrate cancer patients with bone metastases. According to Oslo Cancer Cluster, the marketing authorization provides approval for the commercialization of Xofigo in all 28 countries of the EU, and in Norway, Iceland and Liechtenstein following national approval. The decision […]
